Keywords: elan/biogen, idec, tysabri, maintains, remission, cd, patients

Elan/Biogen Idec's Tysabri maintains remission in CD patients

Article | 30 October 2006

Print This

Ireland's Elan and US drugmaker Biogen Idec say that 93% of Crohn's disease patients on their co-developed drug Tysabri (natalizumab), who ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in